To Partner, or Not to Partner: That is the Question
10 March 2011
Life Science Digest
Traditional wisdom holds that biotechnology companies benefit
from collaborations with their larger pharmaceutical peers, which
can help validate a company's technology, provide capital to help
fund clinical development, and enable access to experienced
clinical, regulatory and commercial infrastructure. While this was
certainly true in the early days of biotechnology, the industry has
now matured - ushering in a new era whereby executives must
carefully weigh the trade-offs between raising capital to go alone
[equity dilution] and sharing economics with a partner [asset
dilution].
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
